tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pasithea Therapeutics Approves Key Proposals at Annual Meeting

Story Highlights
  • Pasithea Therapeutics approved an amendment to increase shares under the 2023 Incentive Plan.
  • Stockholders approved a reverse stock split and ratified CBIZ as the accounting firm.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Pasithea Therapeutics Approves Key Proposals at Annual Meeting

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Pasithea Therapeutics Corp ( (KTTA) ) is now available.

On September 3, 2025, Pasithea Therapeutics Corp. held its Annual Meeting of Stockholders, where several key proposals were approved. These included an amendment to the 2023 Stock Incentive Plan, increasing authorized shares by 1,750,000 to a total of 2,014,221, and the election of two Class II directors. Additionally, stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant decision was also made to adopt an amendment allowing a reverse stock split of the company’s shares, with the ratio to be determined by the Board of Directors. These decisions reflect strategic moves to enhance the company’s financial structure and governance.

More about Pasithea Therapeutics Corp

Average Trading Volume: 148,867

Technical Sentiment Signal: Sell

Current Market Cap: $6.02M

For a thorough assessment of KTTA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1